[go: up one dir, main page]

AR027611A1 - 3-fenil-5-alcoxi-1,3,4-oxodiazol-2-onas substituidas, su produccion y empleo en substancias farmaceuticas - Google Patents

3-fenil-5-alcoxi-1,3,4-oxodiazol-2-onas substituidas, su produccion y empleo en substancias farmaceuticas

Info

Publication number
AR027611A1
AR027611A1 ARP010101037A ARP010101037A AR027611A1 AR 027611 A1 AR027611 A1 AR 027611A1 AR P010101037 A ARP010101037 A AR P010101037A AR P010101037 A ARP010101037 A AR P010101037A AR 027611 A1 AR027611 A1 AR 027611A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
cycloalkyl
aryl
oxodiazol
Prior art date
Application number
ARP010101037A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000110968 external-priority patent/DE10010968A1/de
Priority claimed from DE2001102265 external-priority patent/DE10102265C1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR027611A1 publication Critical patent/AR027611A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/1131,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se describen 3-fenil-5-alcoxi-1,3,4-oxodiazol-2-ona substituidos de la formula (1), en el que equivalen R1 a alquilo C1-6 u cicloalquilo C3-9 substituidos;R2, R3, R4 y R5 a hidrogeno, halogeno, nitro, alquilo C1-4, alquiloxi C1-9, arilo C6-10-alquilo xi C1-4 substituido, ariloxi C6-10, arilo C6-10, cicloalquiloC3-8 o O-cicloalquilo C3-8 o 2-oxo-pirrolidin-1-il, 2,5-dimetilpirrol-1-il o NR6-A-R7 con la condicion que R2, R3, R4 y R5 no sean hidrogenos simultáneamente yal menos uno de los radicales R2, R3, R4 y R5 sea igual al radical 2-oxo-pirrolidin-1-il, 2,5-dimetilpirrol-1-il o NR6-A-R7, con R6 = hidrogeno, alquilo C1-4 oarilo C6-10-alquilo C1-4 substituido, A = enlace simple, COn, SOn o CONH, donde n = 1 o 2; y R7 = hidrogeno, alquilo C1-1 8-alquenilo C2-18 substituido, ariloC6-10-alquilo C1-4, cicloalquilo C5-8-alquilo C1-4, cicloalquilo C5-8, arilo C6-10-alquenilo C2-6, arilo C6-10, difenilo, alquil C1-4-difenilo insanilo, o elgrupo Het-(CH2)r-, con r = 0, 1, 2 o 3 y Het = heterocicl o saturado o insaturado de 5-7 elementos, que puede tener un anillo bencénico condensado y puedesubstituirse, o pueda equivaler a un procedimiento para su produccion. Los compuestos presentan un efecto inhibidor en la lipasa sensible a hormonas, HSL.
ARP010101037A 2000-03-07 2001-03-05 3-fenil-5-alcoxi-1,3,4-oxodiazol-2-onas substituidas, su produccion y empleo en substancias farmaceuticas AR027611A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2000110968 DE10010968A1 (de) 2000-03-07 2000-03-07 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE2001102265 DE10102265C1 (de) 2001-01-18 2001-01-18 Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen

Publications (1)

Publication Number Publication Date
AR027611A1 true AR027611A1 (es) 2003-04-02

Family

ID=26004720

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101037A AR027611A1 (es) 2000-03-07 2001-03-05 3-fenil-5-alcoxi-1,3,4-oxodiazol-2-onas substituidas, su produccion y empleo en substancias farmaceuticas

Country Status (28)

Country Link
US (1) US6369088B2 (es)
EP (1) EP1263745B1 (es)
JP (1) JP2003525931A (es)
KR (1) KR100790763B1 (es)
CN (1) CN1261419C (es)
AR (1) AR027611A1 (es)
AT (1) ATE267184T1 (es)
AU (1) AU784827B2 (es)
BR (1) BR0108974A (es)
CA (1) CA2401953A1 (es)
DE (1) DE50102325D1 (es)
DK (1) DK1263745T3 (es)
EE (1) EE04877B1 (es)
ES (1) ES2218383T3 (es)
HK (1) HK1054036B (es)
HR (1) HRP20020732A2 (es)
HU (1) HUP0302772A3 (es)
IL (1) IL151518A (es)
MX (1) MXPA02008038A (es)
NO (1) NO323483B1 (es)
NZ (1) NZ521207A (es)
PL (1) PL359702A1 (es)
PT (1) PT1263745E (es)
RU (1) RU2281283C2 (es)
SK (1) SK12752002A3 (es)
TR (1) TR200401217T4 (es)
WO (1) WO2001066531A1 (es)
YU (1) YU57802A (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US6900233B2 (en) 2002-02-28 2005-05-31 Aventis Pharma Deutschland Gmbh Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof
DE10208987A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
US20030236288A1 (en) * 2002-02-28 2003-12-25 Karl Schoenafinger Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase
DE10208986A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
SE0203754D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
SE0203753D0 (sv) * 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2006116773A2 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of California Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders
CN101225085B (zh) * 2007-01-17 2011-09-21 天津天士力集团有限公司 苯基呋咱氮类一氧化氮供体型2-苯胺嘧啶衍生物、其制备方法、含有该化合物的组合物及其用途
TW201033163A (en) * 2008-10-20 2010-09-16 Sumitomo Chemical Co Method for manufacturing oxadiazolinone compound and intermediate thereof
WO2010074587A2 (en) 2008-12-23 2010-07-01 Bial - Portela & Ca., S.A. 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use
WO2011108724A1 (ja) * 2010-03-04 2011-09-09 味の素株式会社 糖尿病又は肥満症の予防又は治療剤
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
JP6007417B2 (ja) 2011-05-31 2016-10-12 レセプトス エルエルシー 新規glp−1受容体安定剤および調節剤
US8778923B2 (en) 2011-12-12 2014-07-15 Receptos, Inc. GLP-1 receptor modulators
WO2014201172A1 (en) 2013-06-11 2014-12-18 Receptos, Inc. Novel glp-1 receptor modulators
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
WO2016015014A1 (en) 2014-07-25 2016-01-28 Receptos, Inc. Novel glp-1 receptor modulators
MX381977B (es) 2014-12-10 2025-03-13 Receptos Llc Moduladores del receptor de péptido 1 tipo glucagón.
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN108863774A (zh) * 2018-06-09 2018-11-23 石家庄市绿丰化工有限公司 一种2,4-二氯苯乙酰氯合成的方法
US11203597B2 (en) 2018-11-14 2021-12-21 Altavant Sciences Gmbh Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2299328A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Derives de l'alcoyloxy-5 phenyl-3 oxyde azo
US4076824A (en) 1975-02-03 1978-02-28 Rhone-Poulenc Industries Anthelmintic oxadiazolinone derivatives
FR2299028A1 (fr) 1975-02-03 1976-08-27 Rhone Poulenc Ind Nouvea
DK156439C (da) 1980-09-15 1990-01-22 Shell Int Research 7-substituerede 2,3-dihydrobenzofuranderivater samt pesticidpraeparater indeholdende disse og en fremgangsmaade til bekaempelse af skadelige organismer
EP0067471B1 (en) 1981-06-15 1985-11-06 Shell Internationale Researchmaatschappij B.V. 7-substituted 2,3-dihydrobenzofurans, their preparation and their use as pesticides or as chemical intermediates
US5236939A (en) 1989-09-23 1993-08-17 Bayer Aktiengesellschaft Substituted 1,3,4-oxa(thia)diazolinones process for their preparation and their use of combating endoparasites
DE3931843A1 (de) 1989-09-23 1991-04-04 Bayer Ag Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents

Also Published As

Publication number Publication date
WO2001066531A8 (de) 2002-07-25
EE200200498A (et) 2004-02-16
PT1263745E (pt) 2004-09-30
EP1263745A1 (de) 2002-12-11
HK1054036A1 (en) 2003-11-14
IL151518A0 (en) 2003-04-10
HUP0302772A3 (en) 2007-03-28
AU3378701A (en) 2001-09-17
NO323483B1 (no) 2007-05-21
EP1263745B1 (de) 2004-05-19
RU2281283C2 (ru) 2006-08-10
CN1261419C (zh) 2006-06-28
ES2218383T3 (es) 2004-11-16
SK12752002A3 (sk) 2003-04-01
EE04877B1 (et) 2007-08-15
MXPA02008038A (es) 2004-04-05
DK1263745T3 (da) 2004-08-16
US20010031772A1 (en) 2001-10-18
NZ521207A (en) 2005-04-29
TR200401217T4 (tr) 2004-06-21
NO20024201L (no) 2002-09-03
HK1054036B (zh) 2006-11-17
CA2401953A1 (en) 2001-09-13
PL359702A1 (en) 2004-09-06
KR100790763B1 (ko) 2008-01-03
US6369088B2 (en) 2002-04-09
WO2001066531A1 (de) 2001-09-13
CN1416424A (zh) 2003-05-07
IL151518A (en) 2008-06-05
HRP20020732A2 (en) 2004-12-31
BR0108974A (pt) 2003-06-03
NO20024201D0 (no) 2002-09-03
KR20020079986A (ko) 2002-10-21
DE50102325D1 (de) 2004-06-24
HUP0302772A2 (hu) 2003-11-28
YU57802A (sh) 2005-07-19
AU784827B2 (en) 2006-06-29
JP2003525931A (ja) 2003-09-02
ATE267184T1 (de) 2004-06-15

Similar Documents

Publication Publication Date Title
AR027611A1 (es) 3-fenil-5-alcoxi-1,3,4-oxodiazol-2-onas substituidas, su produccion y empleo en substancias farmaceuticas
DK0794955T3 (da) Hindrede N-oxid-estere af rapamycin samt deres anvendelse som lægemidler
ES2117400T3 (es) Inhibidores de metaloproteinasas.
NO20052469L (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
AR014110A1 (es) Compuestos de 2-aminopiridinas, composiciones farmaceuticas, procedimiento de tratamiento, prevencion e inhibicion
TR200003332T2 (tr) İzoksazolin-3-il-asil benzen üretmek için yöntem
CO5700817A2 (es) Compuesto pentaciclico heteroaromatico y uso medicinal del mismo
DK0770065T3 (da) Trisubstituerede phenylderivater nyttige som PDE IV-inhibitorer
DK0730598T3 (da) Hindrede estere af rapamycin samt deres anvendelse som lægemidler
NZ506101A (en) Tricyclic immunosupressant, anti-allergic and IgE production suppressant compounds
YU34896A (sh) Supstituisani n-(indol-2-karbonil)-glicinamidi, njihovi intermedijeri i farmaceutske kompozicije
PE54294A1 (es) Derivado de 5-aminoalquil-1,4-benzodiazepina
NO970731D0 (no) 2,3-dihydro-1-(2,2,2-trifluoretyl)-2-okso-5-fenyl-1H-1,4-benzodiazepiner
HUP0002330A2 (hu) Azetidinilpropilpiperidin-származékok, ezek intermedierjei és tachikinin antagonistaként történő alkalmazásuk
DE69203797D1 (de) Amidino-Verbindungen, ihre Herstellung und Verwendung als Arzneimittel.
ES2059212T3 (es) Antagonistas paf/h1 imidazopiridina.
EP0665208A4 (es)
LV12824B (lv) Fibrinogēnu receptoru antagonistu iegūšanas paņēmiens
FI852003L (fi) --laktamantibiotika, foerfarande foer deras framstaellning och deras anvaendning som laekemedel eller tillvaextbefraemjare vid boskapsuppfoedning eller som antioxidanter.
DE59107712D1 (de) Säurelabile Lösungsinhibitoren und darauf basierende positiv und negativ arbeitende strahlungsempfindliche Zusammensetzung
DE69621651D1 (de) Azahexan-derivate als substratisostere von retroviralen aspartat-proteasen
FI910058A0 (fi) Fungicider.
ES2171306T3 (es) Compuesto bajo la forma de isomero geometrico puro o de una mezcla de estos isomeros.
PE20000734A1 (es) Compuestos heterociclicos derivados de furopiridina y su uso terapeutico
ATE300532T1 (de) Piperazinon-derivate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal